HTG Molecular Diagnostics (NASDAQ:HTGM) had its price target dropped by research analysts at HC Wainwright from $2.00 to $1.50 in a research note issued on Thursday, BenzingaRatingsTable reports. The firm presently has a “buy” rating on the medical research company’s stock. HC Wainwright’s price target points to a potential upside of 329.92% from the company’s previous close.
A number of other analysts have also weighed in on the stock. Zacks Investment Research raised shares of HTG Molecular Diagnostics from a “sell” rating to a “hold” rating in a research note on Tuesday, March 17th. ValuEngine raised shares of HTG Molecular Diagnostics from a “hold” rating to a “buy” rating in a research note on Tuesday, March 3rd. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $2.43.
Shares of NASDAQ HTGM traded up $0.01 on Thursday, reaching $0.35. 3,396,351 shares of the company traded hands, compared to its average volume of 1,310,445. HTG Molecular Diagnostics has a fifty-two week low of $0.30 and a fifty-two week high of $3.24. The company has a 50 day moving average of $0.49 and a 200 day moving average of $0.67. The company has a current ratio of 5.21, a quick ratio of 5.07 and a debt-to-equity ratio of 0.34. The stock has a market capitalization of $20.32 million, a PE ratio of -0.60 and a beta of 1.33.
HTG Molecular Diagnostics (NASDAQ:HTGM) last posted its earnings results on Wednesday, March 25th. The medical research company reported ($0.01) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.09) by $0.08. HTG Molecular Diagnostics had a negative net margin of 76.97% and a negative return on equity of 88.60%. As a group, research analysts expect that HTG Molecular Diagnostics will post -0.54 earnings per share for the current year.
Several institutional investors and hedge funds have recently modified their holdings of HTGM. Perkins Capital Management Inc. lifted its stake in HTG Molecular Diagnostics by 7.4% in the 4th quarter. Perkins Capital Management Inc. now owns 2,527,000 shares of the medical research company’s stock valued at $1,774,000 after acquiring an additional 173,847 shares in the last quarter. Cowen Prime Services LLC raised its position in shares of HTG Molecular Diagnostics by 2,037.9% in the 4th quarter. Cowen Prime Services LLC now owns 2,137,900 shares of the medical research company’s stock valued at $1,501,000 after buying an additional 2,037,900 shares in the last quarter. Geode Capital Management LLC raised its position in shares of HTG Molecular Diagnostics by 58.3% in the 4th quarter. Geode Capital Management LLC now owns 385,645 shares of the medical research company’s stock valued at $270,000 after buying an additional 142,012 shares in the last quarter. Finally, HighMark Wealth Management LLC acquired a new position in shares of HTG Molecular Diagnostics in the 4th quarter valued at approximately $134,000. 32.38% of the stock is owned by institutional investors and hedge funds.
About HTG Molecular Diagnostics
HTG Molecular Diagnostics, Inc a commercial stage life sciences company, focuses on the precision medicine. The company offers instrumentation (or platforms); consumables comprising assay kits; and software analytics that automate sample processing and profiles various molecular targets. Its platforms generate a molecular profiling library for detection using next-generation sequencing.
Featured Article: Market Indexes
Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.